A Phase 3 Evaluation of Daclatasvir and Sofosbuvir With Ribavirin in Cirrhotic Subjects With Genotype 3 Chronic Hepatitis C Infection
Phase of Trial: Phase III
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 01 Jun 2017 Status changed from active, no longer recruiting to completed.
- 27 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 10 May 2016 Planned primary completion date changed from 1 May 2017 to 1 Feb 2017.